Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Fast-growings companies in Ribociclib
by Most Patent Filing In 5 Years in the world in 2019

The Ribociclib top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filing In 5 Years Ribociclib Fast-growings in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2019, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Basel-Stadt, Switzerland
Dosage form,Health care,Medicine,
...[+2]
Patent: 37
2
Ontario, Canada
Patent: 4
3
Patent: 3
4
Patent: 2
5
Trade partner,Corporate social responsibility,Medicine,
...[+2]
Patent: 2
6
Oncology,Medicine,Health care,
...[+2]
Patent: 2
7
Patent: 2
8
Patent: 2
9
Military science,Materials science,Academic achievement,
...[+2]
Patent: 2
10
Contract research organization,Health care,Liposome,
...[+2]
Patent: 2
11
Patent: 2
12
Patent: 2
13
Noord-Brabant, Netherlands
Patent: 2
14
Patent: 2
15
Patent: 2
16
Tel Aviv, Israel
Gastrointestinal agent,Immunotherapy,Clinical trial,
...[+2]
Patent: 2
17
Active ingredient,Radioimmunoassay,Diagnostic microbiology,
...[+2]
Patent: 1
18
Medicine,Prescription drug,Cardiovascular agent,
...[+2]
Patent: 1
19
Patent: 1
20
Patent: 1
Page generation time: Jul 07 2025